Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer

Basit Öğe Kaydı
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorEbinc, Senar
dc.contributor.authorTunc, Sezai
dc.contributor.authorKalkan, Ziya
dc.contributor.authorOruc, Zeynep
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorKaplan, Muhammet Ali
dc.date.accessioned2024-04-24T17:33:07Z
dc.date.available2024-04-24T17:33:07Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: Metastatic stage gastric cancer is a disease with a poor prognosis and the likelihood of achieving a cure in these patients is low. Treatment response to subsequent-line treatments is poor. We aimed to investigate the effectiveness of the folinic acid, fluorouracil and irinotecan (FOLFIRI) and paclitaxel+carboplatin regimens, which are used in subsequent lines of therapy in advanced-stage gastric cancer.Materials and methods: This study included 40 patients who have metastatic stage gastric cancer and received FOLFIRI or paclitaxel+carboplatin therapy in subsequent lines of therapy between 2017 and 2022. The data of the patients were analyzed retrospectively.Results: At diagnosis median age was 51 (23-88) years. The tumor was localized in the gastroesophageal junction in eight (20%) patients and in other gastric locations in 32 (80%) patients. At diagnosis, 75% (n=30) of the patients presented with the disease in the metastatic stage, while 25% (n=10) presented with stage II -III disease. Regarding the treatments received in the second and further lines of therapy, 18 (45%) patients received paclitaxel+carboplatin and 22 (55%) patients received a FOLFIRI regimen. Of these treatments, 67.5% (n=27) were given as the second line and 32.5% (n=13) were given as third-line therapy. The objective response rate (ORR) was 45.5% in the FOLFIRI arm compared to 16.7% in the paclitaxel+carboplatin arm (p=0.05). Both treatment arms had a median progression-free survival (PFS) of three months (p=0.82). The median overall survival (OS) time was seven months in the FOLFIRI arm compared to eight months in the paclitaxel+carboplatin arm (p=0.71). Side effects were similar between both treatment arms.Conclusion: This study determined that FOLFIRI and paclitaxel+carboplatin treatments have similar OS, PFS, and side effect profiles in subsequent line treatment of gastric cancer. The FOLFIRI treatment regimen yielded a higher ORR.en_US
dc.identifier.doi10.7759/cureus.38837
dc.identifier.issn2168-8184
dc.identifier.issue5en_US
dc.identifier.pmid37303360
dc.identifier.urihttps://doi.org/10.7759/cureus.38837
dc.identifier.urihttps://hdl.handle.net/11468/20441
dc.identifier.volume15en_US
dc.identifier.wosWOS:001007184300005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectComparison Of Chemotherapyen_US
dc.subjectSubsequent -Line Treatmentsen_US
dc.subjectPaclitaxelen_US
dc.subjectFolfirien_US
dc.subjectGastric Canceren_US
dc.titleComparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Canceren_US
dc.titleComparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu